Commentary

The speakers at the Executive Club of Chicago luncheon offered some new economic insights for 2007, but not necessarily foresight on the new Apple iPhone. In the latest edition of Carlini's Comments, columnist James Carlini handicaps their financial forecasts, and bemoans their lack of...

While 2006 was a good year for the overall stock market, it was less kind to the biotech sector and a real mixed bag for the large-cap life science companies in the Midwest. How was it for the far more speculative and risky smaller-cap companies?...

Imagine Imago Scientific Instruments, a shining example of Wisconsin's expertise, creating good-paying jobs and selling its atom probe microscopes worldwide. Actually, there's no need to imagine because it's happening, and Imago's growing space in the global nanotech tools market offers more proof of what the...

Believe it or not, your customers can easily be exposed to abuses of your brand online, which can cause you to lose the goodwill you have established in the market. Organizations can take steps to mitigate some of the damage those abuses can cause, and...

Apple's Steve Jobs has managed, at least temporarily, to change the subject from the backdating of stock options to a revolutionary new multimedia product, the iPhone. Just how revolutionary is the iPhone, and who might it put out of business? Columnist James Carlini offers a...

Podcasts are becoming increasingly popular among content providers and consumers for a variety of reasons, notes Buzz Networks columnist Paul Gibler. If you're considering podcasting entrepreneurship, or simply want to incorporate them into your business or personal life, Gibler offers a few dos and don'ts....

Corporate officers and directors have been found personally liable for IP infringement if they intentionally, actively, and knowingly assist in the corporation's infringement. To minimize those risks, Madison attorney Gina Carter, in this inaugural edition of IP Law, explains the circumstances and scenarios that lead...

Pharma stocks had a mixed performance in 2006, and merger and acquisition activity was the name of the game for the likes of Abbott Labs, 3M, and Monsanto, according to columnist Michael Rosen. In this edition of Yer Biotech Blues, he predicts the M&A trend...

In retrospect, the "Ma Bell" divestiture in 1984 was not such a good idea because we are almost back to square one as another regional bell operating company merges back into AT&T, observes columnist James Carlini. Some believe that net neutrality took it on the...